Compare APLD & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | APLD | PTCT |
|---|---|---|
| Founded | 2001 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3B | 5.3B |
| IPO Year | N/A | 2013 |
| Metric | APLD | PTCT |
|---|---|---|
| Price | $31.32 | $77.48 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 17 |
| Target Price | $29.36 | ★ $73.76 |
| AVG Volume (30 Days) | ★ 27.3M | 2.3M |
| Earning Date | 01-13-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 8.94 |
| Revenue | $173,560,000.00 | ★ $1,779,150,000.00 |
| Revenue This Year | $113.90 | $128.32 |
| Revenue Next Year | $71.28 | N/A |
| P/E Ratio | ★ N/A | $8.64 |
| Revenue Growth | 28.43 | ★ 97.54 |
| 52 Week Low | $3.31 | $35.95 |
| 52 Week High | $40.20 | $87.50 |
| Indicator | APLD | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 61.45 | 54.29 |
| Support Level | $26.86 | $73.03 |
| Resistance Level | $30.30 | $79.03 |
| Average True Range (ATR) | 2.52 | 3.38 |
| MACD | 0.92 | -0.70 |
| Stochastic Oscillator | 93.98 | 29.37 |
Applied Digital Corp is a designer, developer, and operator of next-generation digital infrastructure across North America. It provides digital infrastructure solutions and cloud services to industries like High-Performance Computing (HPC) and Artificial Intelligence (AI). The company operates in the following business segments: Data Center Hosting Business and HPC Hosting Business. The majority of its revenue is generated from the Data Center Hosting Business, which operates data centers to provide energized space to crypto mining customers.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.